Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give written informed consent~* Have a glomerular filtration rate (GFR) ≤ 45 mL/min~* Have an expectation of going on hemodialysis or are already on hemodialysis~* Is serum negative for hepatitis B virus (HBV) antibodies, hepatitis C virus (HCV), and human immunodeficiency virus (HIV)~* Have repeated resting blood pressure measurements ≤ 165/105 mmHg~* Women of childbearing potential must be consistently using a highly effective method of birth control~Exclusion Criteria:~* Women who are pregnant, breastfeeding or planning a pregnancy~* Any previous HBV infection~* Previous vaccination (1 or more doses) with any HBV vaccine~* Any previous autoimmune diseases~* Have a diagnosis of chronic renal failure due to autoimmune disease~* Are at high risk for recent exposure to HBV, HCV or HIV~* Received any antibodies within 3 months prior to study entry~* Ever received an injection with DNA plasmids or oligonucleotides~* Received any vaccines within 4 weeks prior to study entry~* Received any other investigational medicinal agent within 4 weeks prior to study entry

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1018 ISS-HBsAg-Single (Type: EXPERIMENTAL): Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
- 1018 ISS-HBsAg-Double (Type: EXPERIMENTAL): Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)

Based on this trial design, predict the completion outcome and termination type (if applicable).